MedTrace Logo

Tenofovir in HIV/HBV Coinfection

NCT00192595 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-04-01

No results posted yet for this study

Summary

The purpose of the study is to compare the effectiveness of 3 different treatment regimens in reducing or clearing the Hepatitis B Virus in patients infected with HIV and Hepatitis B (co-infection)

Conditions

  • HIV Infection
  • Hepatitis B Coinfection

Interventions

DRUG

Tenofovir

DRUG

Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)

Sponsors & Collaborators

  • The University of New South Wales

    collaborator OTHER

  • Gilead Sciences

    collaborator INDUSTRY

  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • Greg Dore, MBBS, FRACP · National Centre in HIV Epidemiology and Clinical Research.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • Australia
  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00192595 on ClinicalTrials.gov